Clinical Trial: A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799546) titled 'A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy' on Jan. 23.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of HSK39297 tablets compared to eculizumab in Patients with PNH who Are Naive to Complement Inhibitor Therapy.

Study Start Date: Feb. 20

Study Type: INTERVENTIONAL

Condition: PNH

Intervention: DRUG: HSK39297 tablets

200mg QD for 24 weeks

DRUG: Eculizumab Injection

Eculizumab Injection for 24 weeks

Recruitment Status: RECRUITING

Sponsor: Haisco Pharmaceutical Group Co.,...